Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On October 1, 2021, Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of 40,000 nonstatutory stock options to a newly-hired employee as part of their inducement for joining the company. The options are priced at $16.84 per share, equal to the stock's closing price on the grant date. They have a seven-year term, vesting over three years, with one-third vesting after one year and the remainder vesting monthly. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan.
Details
News Market Reaction – DVAX
The recorded move for DVAX in the trading session of this news was +1.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 40,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.
The stock options were granted on October 1, 2021 at an exercise price of
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Dynavax Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301390148.html
SOURCE Dynavax Technologies
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.